SecBot SecBot
8-K ·Filed Nov 4, 2026

ARWR

ARROWHEAD PHARMACEUTICALS, INC.
BULLISH
Impact 5/10
Horizonweeks Processed12d 16h ago SEC0000879407-26-000063
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The refinancing removes the onerous MOIC prepayment penalty and revenue sweeps that capped Arrowhead's strategic flexibility. With lower cash interest and no amortization, the company has greater runway to commercialize REDEMPLO (plozasiran) and advance its pipeline. Monitor the December 31, 2026 10-Q for the full credit agreement and any impact on operating expenses.

DirectionBullish
Confidencehigh
Horizonweeks

Redemplo

◆ Mixed Named in this 8-K
Impact
Phase
Approved (US, FCS); Phase 3 (severe hypertriglyceridemia) ongoing; EU under review
Time to market
Already approved and launched in the US (FDA, November 2025) for FCS. EU decision expected ~2026; SHTG label expansion ~2027 if the Phase 3 readout is positive.
Next catalyst
None dated

What to watchThe main re-rating event for ARWR is the Phase 3 severe-hypertriglyceridemia (SHTG) topline readout, expected around mid-September 2026 per trial estimates, SHTG is a far bigger market than the ultra-rare FCS indication Redemplo was approved for. Also watch the Aug 4, 2026 earnings call for the first real Redemplo launch revenue commentary, the pending EU decision after the April 2026 CHMP opinion, and direct competition from Ionis' olezarsen (which had its own FDA decision date for SHTG on June 30, 2026).

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$61.65
T+0 close · Nov 4, 2026 · via day close
Latest settled
−19.94%
T+5 · $49.36
Vs SPY
−19.02%
α at T+5
Next horizon
T+20
in 16d
  1. T+0 · Nov 4 $61.65entry
  2. T+1 · 12d ago −6.80%α −2.39% · $57.46
  3. T+5 · 6d ago −19.94%α −19.02% · $49.36
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arrowhead Pharmaceuticals refinanced its existing $400M senior secured term loan with Sixth Street, replacing a 15% PIK loan with a new $400M facility at SOFR+5.50% (cash interest). The old loan was repaid at a $68M discount to the contractual minimum prepayment amount. The new facility eliminates revenue-based prepayment sweeps, reduces the minimum cash covenant from $150M to $125M, and extends maturity to November 2031. The refinancing significantly lowers borrowing costs and improves financial flexibility.

Key Financial Metrics

Deal Value
$400.0M
Deal Type
credit_facility

Key Facts

  • New $400M senior secured term loan at SOFR+5.50% (cash interest), replacing 15% fixed PIK loan
  • Old loan repaid at ~$404.4M, a $68M discount from the 2.0x MOIC contractual minimum
  • No scheduled amortization; all principal due November 2, 2031
  • Revenue-based prepayment sweeps eliminated; minimum cash covenant reduced to $125M
  • New facility permits additional convertible debt up to $1.1B or 10% of market cap (capped at $2.5B inclusive of existing $700M converts)

Financial Impact

Annual interest cost reduction from ~$60M (15% PIK on ~$364M) to ~$26M (SOFR+5.50% on $400M, assuming ~1% SOFR), saving ~$34M per year in interest expense

interest expensecash flowdebt maturity profile

Risk Factors

  • The new facility is still secured by substantially all assets, including IP
  • SOFR+5.50% is a high spread, reflecting the company's pre-commercial stage risk profile
  • All $400M principal is due at maturity in 2031, creating refinancing risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000879407-26-000063
Document: arwr-202611048kex991.htm0000879407-26-000063
Document: 0000879407-26-000063-index-headers.html0000879407-26-000063
Document: 0000879407-26-000063-index.html0000879407-26-000063
Document: 0000879407-26-000063.txt0000879407-26-000063

Track record

7 reports on ARWR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $47.78 to $44.21 Now $44.21 +7.47% ▲ +7.47% +5.56% vs SPY
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $57.46 to $58.16 Now $44.21 −23.06% ▲ +1.22% +0.91% vs SPY
  3. Nov 4, 202612d ago 8-K Bullish 5/10 Viewing Entry $61.65 to $57.46 Now $44.21 −28.29% ▼ −6.80% −2.39% vs SPY
  4. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $59.53 to $61.65 Now $44.21 +25.73% ▼ −3.56% −1.91% vs SPY
  5. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $82.76 to $82.85 Now $44.21 −46.58% ▲ +0.11% −0.74% vs SPY
  6. Aug 20, 202612w ago Insider Cluster Neutral 2/10 Entry $87.11 to $86.73 Now $44.21 −49.25% ▼ −0.44% −0.14% vs SPY
  7. Jun 16, 202621w ago 8-K Neutral 2/10 Entry $81.04 to $81.82 Now $44.21 −45.45% ▲ +0.96% +0.18% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens Wed (9h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026